Humana Inc. (NYSE:HUM) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. trimmed its stake in Humana Inc. (NYSE:HUM) by 7.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 587,672 shares of the insurance provider’s stock after selling 47,226 shares during the quarter. Humana makes up 0.7% of Jacobs Levy Equity Management Inc.’s portfolio, making the stock its 27th biggest holding. Jacobs Levy Equity Management Inc. owned approximately 0.49% of Humana worth $186,139,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Mendota Financial Group LLC raised its position in shares of Humana by 9.2% during the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock worth $119,000 after purchasing an additional 27 shares during the period. Capital Advisors Ltd. LLC raised its position in shares of Humana by 17.0% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after purchasing an additional 31 shares during the period. CarsonAllaria Wealth Management Ltd. raised its position in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares during the period. Moors & Cabot Inc. grew its holdings in Humana by 2.5% in the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after buying an additional 40 shares in the last quarter. Finally, Harbour Investments Inc. grew its holdings in Humana by 10.5% in the 2nd quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock worth $161,000 after buying an additional 41 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

Shares of NYSE:HUM opened at $293.09 on Tuesday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $502.73. The business has a fifty day simple moving average of $275.33 and a 200 day simple moving average of $329.24. The firm has a market cap of $35.29 billion, a price-to-earnings ratio of 25.96, a P/E/G ratio of 2.34 and a beta of 0.53.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The business had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. As a group, sell-side analysts predict that Humana Inc. will post 15.86 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.21%. Humana’s dividend payout ratio (DPR) is currently 31.36%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price objective on shares of Humana in a report on Tuesday, October 1st. KeyCorp assumed coverage on Humana in a report on Friday, October 11th. They issued a “sector weight” rating for the company. Leerink Partnrs lowered Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a report on Tuesday, October 8th. Finally, TD Cowen increased their price objective on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Twenty equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.